8x8 Inc vs Liquidia Corporation Common Stock — how do they compare? 8x8 Inc trades at $2.02 (market cap $290.32M), while Liquidia Corporation Common Stock trades at $33.47 (market cap $3.04B). The key difference: Liquidia Corporation Common Stock is far larger — about 10.5× 8x8 Inc's market cap, and 8x8 Inc is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and Liquidia Corporation Common Stock for 0 Days on average.
| EGHT | LQDA | |
|---|---|---|
Market Cap | $290.32M | $3.04B |
Volume | 1,226,387 | 21,111,778 |
Sector | Technology | Health |
52-Week High | $2.76 | $91.03 |
52-Week Low | $1.59 | $22.02 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $557.24M | $2.94B |
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.05, up 0.49% with a bullish technical signal despite bearish moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent news highlights cost-saving client wins and AI platform growth, while analyst consensus remains divided with a $19.77 price target representing significant upside potential from current levels.
EGHT presents a high-risk, high-reward opportunity with substantial upside to analyst targets but faces execution risks amid negative earnings. The stock's low price-to-sales ratio of 0.39 suggests undervaluation, though high debt levels and thin margins require careful monitoring. Positive momentum in AI adoption and client acquisitions could drive revaluation if profitability targets are met.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →